Osimertinib Mesylate Intermediate CAS 1421373-66-1
| Items |
Standards |
Results |
| Appearance |
White to light yellow solid powder |
Light yellow solid powder |
| Identification |
By IR |
Complies |
| |
By HPLC |
Complies |
| Solubility |
Soluble in Dimethylsulfoxide,slightly soluble in Ethanol and Acetonitrile,with pH dependent aqueous solubility |
Complies |
| Water Content(KF) |
≤ 1.00% |
0.38% |
| Residue on Ignition |
≤ 0.10% |
0.07% |
| Heavy Metals |
≤ 20ppm |
Complies |
| Mesylate |
15.20%~18.20% |
17.20% |
| Residual Solvents |
Acetonitrile: ≤410ppm |
ND |
| |
Acet: ≤5000ppm |
2500ppm |
| |
Tetrahydrofuran: ≤720ppm |
ND |
| Related Substances |
Maximum single impurity: ≤0.20% |
0.05% |
| |
Total impurities: ≤1.00% |
0.08% |
Assay (HPLC basis on drying) |
98.00%~102.00% |
99.96% |
| Particle Size |
D90: ≤100µm |
Complies |
| Reference Standard |
In-house Standard |
| Conclusion |
The product complied to In-house standard. |
| Storage |
Preserve in tight,light-resistant containers in a cool place |
Product Overview
Osimertinib Mesylate is a potent EGFR (Epidermal Growth Factor Receptor) inhibitor, specifically classified as a third-generation, covalent, irreversible, and mutation-selective agent designed for advanced cancer treatment applications.
Primary Applications
- Cancer Treatment: Primarily used in the treatment of non-small cell lung cancer (NSCLC) that has developed resistance to first- and second-generation EGFR inhibitors, particularly those harboring the T790M mutation.
- Therapeutic Agent in Clinical Trials: Currently being investigated in clinical trials for other types of cancers, exploring its potential as a broad-spectrum antitumor agent.
- Combination Therapy: Researchers are exploring the use of Osimertinib Mesylate in combination with other therapies to enhance treatment efficacy and overcome resistance.
Key Mechanisms of Action
- Inhibition of EGFR Mutations: Binds covalently and irreversibly to the EGFR, particularly the T790M mutation, effectively inhibiting its signaling pathways and tumor growth.
- Improved Patient Outcomes: By targeting resistant EGFR mutations, Osimertinib Mesylate has demonstrated improved progression-free survival and overall survival in clinical trials.
- Minimal Off-Target Effects: Mutation-selective properties minimize off-target effects, reducing potential adverse reactions and improving treatment
- Packaging Options
Powder Form:
1kg Aluminum Foil Bag
25kg Drum/Bag
Liquid Form:
1L Bottle
25L Drum
200L Drum
OEM & ODM packaging services available
Shipping Recommendations
- ≤50kg: Express delivery recommended (DDU service)
- ≤500kg: Air shipping recommended (CIF service)
- >500kg: Sea shipping recommended (FOB, CFR, or CIF service)
- For high-value products: Air shipping and express delivery recommended for safety
We accept customer-specified shipping methods and can recommend the optimal shipping solution to ensure safe and timely delivery of your products.
Frequently Asked Questions
Can I get a free sample?
We can provide free samples; customers only need to pay for shipping costs.
How can I trust your company?
Our ownership team has over 16 years of experience in chemical raw materials. We have established long-term relationships with customers and partners through consistent quality and reliable service. Our vision is to obtain wide customer recognition through high-quality procurement and exceptional service.
How do you guarantee product quality?
All products comply with national and international testing standards. Quality certificates are available upon request.
Can you use customer-specific labeling and packaging?
Yes, we accommodate custom labeling and packaging requirements. Please provide your specifications and we will assist accordingly.
What is your delivery time and method?
We typically ship within 3-5 working days after payment confirmation. Shipping options include sea, air, or express delivery with door-to-door service available.